Gilead Sciences, Inc. (NASDAQ:GILD) closed its last session at $86.55 with the change of +1.26%. The market capitalization of the company is $115.27B with an average Volume of 9.53 million shares. The stock currently has its 52-Week High range of $120.37 and 52-week low range of $77.92. The Price to Book (P/B) ratio stands at 8.60. The stock traded total quantity of 7.63 million shares.
For the current Fiscal Quarter, 21 analysts have given an average earnings per share forecast of $3.01. The Low Earnings per share estimate of the current Quarter is $2.72 and High Estimate is set at $3.32 according to these Analysts opinions. The Previous Year EPS of this Quarter is $3.15.
According to 18 analysts, an average sales Estimate of the current Fiscal quarter is $7.79B. The lower sales estimate is $7.42B and higher sales estimate is $8.23B according to these Analysts thoughts.
The Company currently has Highest Price Target of $135 and Lowest Price Target of $81. It has Median Price Targets of $115. Mean price target is set at $110.58 after consensus analysis of 19 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month 6 analysts have assigned this stock as Strong Buy where 10 assigned Buy, 9 analysts believe it’s a Hold, 0 said Underperform and 0 assigned Sell rating.
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) ended its last trade at $5.47 with the move of +0.55%. The company has market value of $382.60M with the total traded volume of 1.39 million. The stock currently has its 52-Week top value of $11.15 and 52-week down value of $3.61. The price to book (P/B) ratio of the company is 4.86. Its previous closing price was recorded at $5.44.